Other languages Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
3.12 ^USD	+5.76%		+1.30%	-24.64%

Jun. 05	Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target	MT
May. 08	Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor	Jan. 04
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer	Jan. 03
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Relmada Therapeutics Reports Positive Preclinical Data on its Psilocybin Program to Treat Liver Disease	23-10-11
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023	23-10-11
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board	23-09-06
Relmada Therapeutics Doses First Person in Phase 3 Trial of REL-1017 for Major Depressive Disorder	23-08-23
Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder	23-08-23
Relmada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of Directors	23-01-12
Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical Officer	23-01-09
Relmada Therapeutics, Inc. Enters into Amendment No.2 to the License Agreement	22-12-28
Sector Update: Healthcare Stocks Adding to Earlier Gains Near Close Thursday	22-12-08
Top Midday Decliners	22-12-08
Sector Update: Health Care Stocks Extending Thursday Advance	22-12-08
Sector Update: Health Care Stocks Edge Higher Pre-Bell Thursday	22-12-08
Sector Update: Health Care	22-12-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Other languages

Filters